Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Medivation Completes Enrollment In Confirmatory, Pivotal Phase 3 'CONNECTION' Trial Of Dimebon In Patients With Alzheimer's Disease
Medivation, Inc. (Nasdaq: MDVN) announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer"s disease.
generic viagra online
New Drug Blocks Common Cancer Pathway
SCIENTISTS have developed a new drug which can reduce the growth of tumours* in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.
News of the day
Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
Endocrinology

Check Your Eyes Before It's Too Late

People have the opportunity to have their eyes checked with one-of-a-kind equipment for free, while helping to solve the mystery behind the leading cause of blindness in Australia. Even people with healthy eyes, aged 50 and over, are being encouraged to participate in the Queensland University of Technology study. Eye specialist and QUT researcher Dr Beatrix Feigl is embarking on the study to detect the early signs of age-related macular degeneration, a disease that progressively causes vision loss. Dr Feigl has received an inaugural Vice-Chancellor Fellowship to help conduct the research. "Macular degeneration is the leading cause of blindness in Australia and one in three Australians will be affected to some degree by it," Dr Feigl said. "As yet there is no cure, but if it is detected early enough, steps can be taken to prevent the condition from worsening. "It"s very important to detect the condition before there is damage because you can only preserve existing eyesight." Dr Feigl will use extremely sensitive, non-invasive instruments which are unique to QUT to look for early signs of macular degeneration. "People can have their vision measured for free with tests not available anywhere else in Australia," she said. "It"s a very thorough eye test with immediate feedback. "We need people with healthy eyes to help find early detection measures." Dr Feigl said general health and genetics influenced a person"s chance of developing the eye disease. "Smoking and a poor diet low in vitamins and omega-3 can increase the risk," she said. "Also, if you know one of your parents had age-related macular degeneration, it is worth taking extra care of your eyes. "And always be sure to have your eyes tested while they are still healthy." Queensland University of Technology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009